Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Zanubrutinib Faces Off Against Ibrutinib in CLL Trial

January 8th 2020

Armed with the knowledge that inhibition of the Bruton tyrosine kinase is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib, in 2 leukemia and lymphoma subtypes.

Woyach Highlights Progress and Next Steps in CLL Paradigm

January 8th 2020

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

January 8th 2020

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

Dr. Woyach on the Results of the ELEVATE-TN Trial in CLL

January 7th 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Woyach on Frontline Treatment Options in CLL

January 3rd 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Final Thoughts From ASH 2019 in CLL

December 24th 2019

Novel Combinations in Development for CLL

December 24th 2019

PI3K Inhibitors in R/R CLL

December 24th 2019

BTK Inhibitors in R/R CLL

December 24th 2019

Venetoclax in R/R CLL

December 24th 2019

Progression on Frontline Ibrutinib in CLL

December 24th 2019

Resistance Mechanisms Associated With BTK Inhibitors

December 24th 2019

Ibrutinib + Venetoclax for Frontline CLL

December 24th 2019

MRD Testing for CLL

December 24th 2019

Obinutuzumab + Venetoclax for Frontline CLL

December 24th 2019

Comparison of BTK Inhibitors for CLL

December 24th 2019

Toxicities With BTK Inhibitors for CLL

December 24th 2019

Frontline Antibodies With BTK Inhibitors for CLL

December 24th 2019

Up-front Ibrutinib Versus FCR for Patients With CLL

December 24th 2019

Risk Assessment in Newly Diagnosed CLL

December 24th 2019